The endoplasmic reticulum aminopeptidase ERAAP is involved in the final trimming of peptides for presentation by MHC class I (MHC-I) molecules. Herein, we show that ERAAP silencing results in MHC-I peptide-loading defects eliciting rejection of the murine T-cell lymphoma RMA in syngeneic mice. Although CD4 and CD8 T cells are also involved, rejection is mainly due to an immediate NK cell response and depends on the MHC-I-peptide repertoire, since replacement of endogenous peptides with correctly trimmed, high affinity peptides is sufficient to restore an NKprotective effect of MHC-I molecules through the Ly49C/I NK inhibitory receptors. At the crossroad between innate and adaptive immunity, ERAAP is therefore unique in its two-tiered ability to control tumor immunogenicity. Because a large fraction of human tumors express high levels of the homologous ERAP1 and/or ERAP2, the present findings highlight a convenient, novel target for cancer immunotherapy.
Introduction
Antigenic peptides are generated in the cytoplasm as proteolytic intermediates by degradation of endogenous proteins through the multicatalytic proteasome and other proteases (1) .
Proteolytic intermediates are then translocated into the endoplasmic reticulum (ER) by the Transporter Associated with Antigen Processing (TAP) and further processed by ER aminopeptidases, i.e. ERAAP in mice (2) and ERAP1 and ERAP2 in humans (3) (4) (5) , before being loaded onto MHC-I molecules.
Inhibition or loss of cytoplasmic proteases, the TAP transporter and components of the peptide loading complex results in the marked down-regulation of MHC-I expression on the cell surface (6) (7) (8) (9) (10) . In contrast, inhibition of ER aminopeptidases by siRNA or in ERAAP-knockout mice causes a partial suppression not exceeding 60% on MHC-I surface expression (2, 5 ). Yet,
immunization of ERAAP-knockout mice with cells from wild-type mice or vice versa, results in potent CD8
+ T-cell responses (11, 12) , suggesting qualitative and quantitative alterations in the peptide-MHC (pMHC) class I repertoire. Consistent with these findings, mass spectrometry analysis revealed a marked increases in the length of endogenous peptides presented by MHC-I in mice lacking ERAAP (13) , but whether or not ERAAP-dependent p-MHC alterations affect innate immune responses is presently unknown.
In agreement with the above studies, we have previously observed that an altered expression of ERAP1 and ERAP2 in human tumors as compared to their normal counterparts (14) results in an abnormal MHC-I expression (15) , but how this might affect host immune responses against tumors (either adaptive or innate) it is presently unknown.
To address this issue, ERAAP expression was stably reduced in the murine T-cell lymphoma RMA by transfection of ERAAP-targeted microRNA. Taking advantage of in vivo and ex vivo molecular and functional studies we show herein that ERAAP-silenced RMA cells are readily rejected by syngeneic mice mainly through a tumor-specific NK cell response, due to poor pMHC-I engagement of Ly49C/I NK inhibitory receptors.
Materials and Methods

Mice and cell lines
Six-to eight-week-old inbred female C57BL/6 (Charles Rivers Laboratories) and C57BL/6 nude (Taconic) mice were maintained at the Animal Resource Facilities in accordance with the experimental ethics committee guidelines. RMA (16) 
Flow cytometry, immunofluorescence, protein biochemistry and aminopeptidase activity
Flow cytometry was performed on FASCalibur and FASCantoII (BD-PharMingen). Acetonefixed tumor sections were stained with specific mAbs and analysed by confocal microscope.
Western blotting, microsomal aminopeptidase activity tests, pulse-chase and in vitro assembly were were performed as described (15, 26, 27 The rate of generation of newly assembled pMHC-I complexes, the dissociation of preformed pMHC-I complexes and the replacement of the endogenous MHC-I binding-peptides were detected as described (11, 25, 28 
IL-2 activated splenocytes
Single-cell suspensions from C57BL/6 spleens were cultured (15x10 6 cells/ml) with 100 ng/ml recombinant human IL-2 (PeproTech) for 7 days. The cells were sorted on FACSAria by gating on NK1.1 + CD3 -Ly49C/I + and NK1.1 + CD3 -Ly49C/I -and then cultured (2 x 10 6 /ml) for 40 h with IL-2 and used as cytotoxicity effectors (25) .
NK functional assays
NK cell cytotoxic activity was evaluated by a standard 5-h 51 Cr release assay (31) . The degranulation assay was performed by co-culturing target and effector cells at a 1:1 ratio for 6 h in the presence of GolgiStop (BD) and anti-CD107a (32-35), as described in detail in Supplementary Materials. 
Results
Down-regulation of ERAAP affects MHC-I surface expression in RMA cells.
To assess the relevance of ER peptide trimming on tumorigenicity, we stably suppressed the expression of ERAAP in the murine T-cell lymphoma RMA of C57BL/6 origin by transfection of vectors encoding GFP in combination with microRNAs to either ERAAP (RMAsiERAAP) or a control, scrambled sequence (RMA-scramble). ERAAP mRNA levels were similar in parental cells and 10 RMA-scramble clones, but were decreased, although to a different extent, in 31 distinct RMA-siERAAP clones ( Supplementary Fig. S1 ). Eight representative RMAsiERAAP clones and one RMA-scramble clone selected at random (hitherto RMA-sc) were selected and tested by Western blotting, to confirm specific ERAAP down-regulation at the protein level. RMA-siERAAP clone 22 (RMA-siERAAP-22) showed the lowest ERAAP levels, corresponding to a relative decrease of 90% compared to the parental RMA cells and RMA-sc, while RMA-siERAAP clones 5, 6, 28 and 50 showed a less pronounced down-regulation (Fig.   1A ). Aminopeptidase activity in isolated microsomes from 3 representative RMA-siERAAP clones and control cells, RMA-sc and RMA cells, was proportional to the amount of the aminopeptidase expressed, while essentially no substrate cleavage was seen in microsomes from RMA cells treated with Leu-SH, a specific aminopeptidase inhibitor (Fig. 1B) . MHC-I surface expression was decreased in these RMA-siERAAP clones by 48.5 to 56%, as assessed by mAb K204, while no change in the expression of control surface markers CD5 and CD45 was detected (Fig. 1C) . MHC-I expression was similarly reduced (52%) in RMA cells treated with Leu-SH (Fig. 1C) Much lower K b levels and a >85% decrease in the mature glycan component were instead detected in RMA-S cells, as expected (37, 38) .
To investigate heavy chain stability and association with β2m, detergent-soluble H2-K (Fig. 2C and Supplementary Fig. S2B ).
During the same period, the MHC-I dissociation rate was faster in RMA-siERAAP clones 5 and 22 as compared to RMA and RMA-sc cells (Fig. 2D) , suggesting that a greater fraction of surface MHC-I in RMA-siERAAP cells is unstable.
Altogether, these results demonstrate that the down-regulation of surface MHC-I expression in RMA-siERAAP cells is due both to a stoichiometric loss of MHC-I molecules since early biosynthetic stages and to the instability of pMHC-I complexes on the cell surface.
In vivo evaluation of host immune responses against RMA-siERAAP cells
To investigate whether ERAAP deficiency affects RMA tumorigenicity, we subcutaneously inoculated RMA-siERAAP-22, RMA-sc, RMA, and RMA-S cells in syngeneic C57BL/6 mice. All mice injected with control RMA and RMA-sc cells developed progressively enlarging tumors and died within 32 days, whereas mice injected with RMA-siERAAP-22 and RMA-S did not develop palpable tumors in most cases (Fig. 3A,B) . Only 3/10 mice injected with RMA-siERAAP-22 and 2/10 mice injected with RMA-S developed palpable tumors within 15 days after inoculation (Fig. 3A,B ). Of these, one RMA-siERAAP-22 and both RMA-S tumors completely regressed in a few days, whereas the remaining 2 RMA-siERAAP-22 tumors grew very slowly and had not killed their hosts by day 50.
Rejection of RMA-siERAAP-22 is likely mediated by a host immune response, since the in vitro proliferation rates and apoptotic state of RMA-siERAAP-22, RMA and RMA-sc cells were very similar ( Supplementary Fig. S3A,B) . In line with this interpretation, confocal microscopy revealed a significant increase of tumor-infiltrating NK1. growth to RMA-sc levels. In contrast, the effect of double CD4 + /CD8 + depletion was marginal during the first 17 days (Fig. 4C) , and resulted in delayed tumor growth and death of 60% of mice 29 days after challenge (Fig. 4D) . Treatment with an irrelevant IgG did not affect tumor rejection (Fig. 4) . Finally, C57BL/6 nude mice efficiently rejected RMA-siERAAP-22 and RMA-S cells as immunocompetent mice, emphasizing the minor contribution of CD4 + and CD8 + T cells to tumor control ( Supplementary Fig. S4 ). Fig. 6 and Supplementary Fig. S5 ).
Similar to subcutaneous injection experiments ( Fig. 3 and 4) , RMA-siERAAP-22 cells were rejected, but they grew in NK1.1-depleted mice like RMA-sc cells grow in control mice (Fig. 6A) . Interestingly, GFP + RMA-siERAAP-22 cells began to decrease at 12 hours in the peritoneal cavity, and disappeared almost completely at 48 hours ( with RMA-siERAAP-22 at 4 h (Fig. 6C) , i.e. coinciding with the beginning of apoptotic decline.
Likewise, the virtual absence of NK1.1 + /CD3 + PE cells ruled out an unlikely involvement of NKT cells in tumor rejection (Fig. 6C) .
These results conclusively document the direct participation and major role of NK cells at early stages of RMA-siERAAP tumor control and demonstrate that 12 h following tumor challenge are sufficient to provide PE cells with the ability to kill RMA-siERAAP cells.
Ex vivo evaluation of NK immune responses induced by RMA-siERAAP cells
To (Fig. 6D ). PE cells from mice inoculated with saline were poor effectors and failed to reveal any difference in NK susceptibility among YAC-1, RMA-S, RMA-sc and RMA-siERAAP-22. In contrast, PE cells from mice inoculated with either tumor were much better effectors for all the four targets, particularly for YAC-1 and RMA-siERAAP-22 after 4 hours and 12 hours from injection, respectively. This increased lytic activity was further confirmed by a degranulation assay (Fig. 6E) .
Next, we assayed the ability of PE cells from mice inoculated with RMA-siERAAP-22 to kill RMA-siERAAP-22 in which the endogenous MHC-I peptides were exchanged by incubation with a large excess of the high-affinity peptides ASNENMETM (23) and SIINFEKL (22) . As expected, the MHC-I-specific K204 mAb did not detect any significant difference regardless of the peptide added. In contrast, mAb 25-D1.16 (29) specific to the H-2K b /SIINFEKL complex revealed an efficient SIINFEKL peptide exchange on the cell surface (Fig. 7A ). Most interestingly, both peptides, but not the irrelevant SLYNTVATL ligand, totally protected RMAsiERAAP-22 from PE cell-mediated lysis (Fig. 7B) 
Discussion
Herein, ERAAP down-regulation in RMA lymphoma cells was shown to induce NK cellmediated, and subsequently T cell-mediated (CD4 as well as CD8), rejection in syngeneic mice.
To our knowledge, this is the first demonstration that ERAAP regulates tumorigenicity. CD8 involvement might have been anticipated from previous studies, since in ERAAP knockout mice a marked alteration in the pMHC-I repertoire (11, 12) , resulted in potent CD8 T cell responses. In contrast, a major NK cell triggering effect was particularly surprising and totally unanticipated, since ERAAP down-regulation caused a modest (about 50%) suppression of MHC-I expression in all studies (2, 11, 12, 36) including the present one.
Our RMA-siERAAP clones display alterations in MHC-I surface expression and surface turnover similar to those seen in knockout mice (11, 36) . In addition, these clones show a progressive stoichiometric loss of MHC-I molecules, evident since early biosynthetic stages, resulting in a reduced accumulation of β 2 m-associated, conformed heavy chains. These alterations are much slighter than those seen in TAP-defective RMA-S cells (16) , and yet they indirectly document a subtle conformational change that appears to be sufficient to completely derange MHC-I interactions with the prominent NK receptor and MHC-I folding sensor Ly49C/I. This effect is not due to a simple quantitative reduction in surface MHC-I, as in vitro assembly and in vivo pulse with canonical, trimmed peptides rescued peptide-specific conformational epitopes, as well as receptor engagement. It is also highly unlikely to result from a direct interference of an 
ERAAP knockouts (11), the presently described decreases in MHC-I stability, β 2 m association, and intracellular transport, as well as the peptide-reversible susceptibility to NK cell lysis of RMA-siERAAP cells, are fully consistent with crystallographic models of peptidedriven/conformation-dependent Ly49C engagement.
In summary, and quite strikingly, MHC-I molecules synthesized in cells impaired in Nterminal peptide trimming have been shown by others to be sufficiently conformed to present antigen to CD8 T cells (12) , and by us to be insufficiently conformed to inhibit NK cells. Our immune subset depletion experiments provide in vivo evidence for both mechanisms, NK cell killing of tumor cells being clearly preponderant and occurring at an earlier stage than CD4-mediated and CD8-mediated rejection. Indeed, by inciting recognition of missing self and altered self at the same time, ERAAP appears to regulate tumor immunogenicity at a crucial crossroad between innate and adaptive immunity. 
